SYNOX THERAPEUTICS
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
SYNOX THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2020-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.synoxtherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
153.91 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Font API WordPress Content Delivery Network ReCAPTCHA Cloudflare JS CDN JS Contact Form 7
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Investors List
Hercules Capital
Hercules Capital investment in Debt Financing - SynOx Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - SynOx Therapeutics
HealthCap
HealthCap investment in Series B - SynOx Therapeutics
Bioqube Ventures
Bioqube Ventures investment in Series B - SynOx Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series A - SynOx Therapeutics
Medicxi
Medicxi investment in Series A - SynOx Therapeutics
Gimv
Gimv investment in Series A - SynOx Therapeutics
HealthCap
HealthCap investment in Series A - SynOx Therapeutics
Official Site Inspections
http://www.synoxtherapeutics.com Semrush global rank: 7.77 M Semrush visits lastest month: 718
- Host name: 172.67.164.64
- IP address: 172.67.164.64
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SynOx Therapeutics"
About us – Synox | Website
At GlaxoSmithKline, Elyse held multiple vice president roles, shaping clinical strategies and overseeing a global organization responsible for delivering a diverse R&D portfolio. Elyse practiced clinical medicine with a specialty in …See details»
SynOx Therapeutics - Crunchbase Company Profile
Organization. SynOx Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; SynOx Therapeutics …See details»
SynOx Therapeutics - LinkedIn
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other …See details»
SynOx Therapeutics Adds New Investor and Capital to Series B …
Oct 30, 2024 SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the …See details»
SynOx Therapeutics - Products, Competitors, …
Synoxtherapeutics.com. Overview & Products; Financials; People; Founded Year 2020. Stage Series B - II | Alive. Total Raised $135.77M. Last Raised $17M | 1 mo ago. About SynOx Therapeutics. SynOx Therapeutics focuses on the …See details»
SynOx Therapeutics - Company Profile & Staff Directory
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other …See details»
SynOx Therapeutics - Seedtable
SynOx Therapeutics, based in Dublin, is developing a specialized treatment for diffuse tenosynovial giant cell tumors, a rare condition. By targeting this niche, SynOx offers a solution …See details»
SynOx Therapeutics, Ltd. | Life Sciences PA
SynOx Therapeutics Limited is a Dublin and Oxford-based, late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for …See details»
SYNOX THERAPEUTICS LIMITED
Find company research, competitor information, contact details & financial data for SYNOX THERAPEUTICS LIMITED of DUBLIN. Get the latest business insights from Dun & Bradstreet.See details»
SynOx Therapeutics - VentureRadar
Similar Companies: Humanigen USA n/a We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are …See details»
SynOx Therapeutics - PitchBook
SynOx Therapeutics General Information Description. Developer of humanized monoclonal antibodies intended to significantly improve the lives of people living with Tenosynovial giant …See details»
SynOx Therapeutics Adds New Investor and Capital to Series B …
Www.synoxtherapeutics.com | [email protected] Page 2 As part of the Series B extension, Arthur Franken, general partner at Gilde Healthcare, will join the SynOx Board of …See details»
SynOx Therapeutics - Overview, News & Similar companies
SynOx Therapeutics contact info: Phone number: +44 2080784357 Website: www.synoxtherapeutics.com What does SynOx Therapeutics do? Based out of Dublin, …See details»
Synox Therapeutics Limited - medicxi.com
SynOx is developing Emactuzumab, an anti-CSF1 Receptor targeted monoclonal antibody licenced from Roche Pharmaceuticals. SynOx is initially focussing on Tenosynovial Giant Cell …See details»
Series A - SynOx Therapeutics - 2020-11-19 - Crunchbase
Nov 19, 2020 Organization Name . SynOx Therapeutics . Announced Date Nov 19, 2020; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . obfuscated. …See details»
Nextsource | Company Profile | SynOx Therapeutics
Explore the company profile of SynOx Therapeutics (synoxtherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
SynOx Therapeutics raises €37M in Series A Financing
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of …See details»
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc.
19 hours ago Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical …See details»
Parexel CEO Peyton Howell leads CRO's shift to patient-focused …
16 hours ago Howell’s work in drug development began more than 30 years ago. Patient access was at the center of her academic career and later served as the focus when she founded …See details»
Research & Development – Synox | Website
There are generally two types of TGCT: localised TGCT and diffuse TGCT, which is less common and more difficult to treat. The estimated global incidence of TGCT overall is 43 cases per …See details»